211 related articles for article (PubMed ID: 19271030)
1. Future trends in the treatment of serious Gram-positive infections.
Metzger R; Bonatti H; Sawyer R
Drugs Today (Barc); 2009 Jan; 45(1):33-45. PubMed ID: 19271030
[TBL] [Abstract][Full Text] [Related]
2. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
Napolitano LM
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
[TBL] [Abstract][Full Text] [Related]
3. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
Jones RN; Low DE; Pfaller MA
Diagn Microbiol Infect Dis; 1999 Feb; 33(2):101-12. PubMed ID: 10091033
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.
Lee SY; Kuti JL; Nicolau DP
Surg Infect (Larchmt); 2005; 6(3):283-95. PubMed ID: 16201938
[TBL] [Abstract][Full Text] [Related]
5. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
Rubinstein E; Bompart F
J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
[TBL] [Abstract][Full Text] [Related]
6. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
[TBL] [Abstract][Full Text] [Related]
7. National surveillance of antimicrobial resistance among Gram-positive bacteria in Saudi Arabia.
Shibl AM; Memish ZA; Kambal AM; Ohaly YA; Ishaq A; Senok AC; Livermore DM
J Chemother; 2014 Feb; 26(1):13-8. PubMed ID: 24091308
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial resistance trends among 5608 clinical Gram-positive isolates in China: results from the Gram-Positive Cocci Resistance Surveillance program (2005-2010).
Zhao C; Sun H; Wang H; Liu Y; Hu B; Yu Y; Sun Z; Chu Y; Cao B; Liao K; Lei J; Hu Z; Zhang L; Zhang X; Xu Y; Wang Z; Chen M
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):174-81. PubMed ID: 22521693
[TBL] [Abstract][Full Text] [Related]
9. Newer treatment options for skin and soft tissue infections.
Raghavan M; Linden PK
Drugs; 2004; 64(15):1621-42. PubMed ID: 15257625
[TBL] [Abstract][Full Text] [Related]
10. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
Garrison MW; Neumiller JJ; Setter SM
Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
[TBL] [Abstract][Full Text] [Related]
11. Novel agents for resistant Gram-positive infections--a review.
Strahilevitz J; Rubinstein E
Int J Infect Dis; 2002 Mar; 6 Suppl 1():S38-46. PubMed ID: 12044288
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
13. Quinupristin-dalfopristin.
Bryson HM; Spencer CM
Drugs; 1996 Sep; 52(3):406-15. PubMed ID: 8875130
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial resistance in gram-positive bacteria.
Rice LB
Am J Med; 2006 Jun; 119(6 Suppl 1):S11-9; discussion S62-70. PubMed ID: 16735146
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them.
Salzer W
Perit Dial Int; 2005; 25(4):313-9. PubMed ID: 16022084
[TBL] [Abstract][Full Text] [Related]
16. [Update of antimicrobial resistance in Gram-positive microorganisms].
Cercenado E
Med Clin (Barc); 2010 Dec; 135 Suppl 3():10-5. PubMed ID: 21477699
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
Jones RN; Fritsche TR; Sader HS; Goldstein BP
J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
[TBL] [Abstract][Full Text] [Related]
18. [Epidemiology of the infection by resistant Gram-positive microorganisms].
Cercenado E
Rev Esp Quimioter; 2016 Sep; 29 Suppl 1():6-9. PubMed ID: 27608305
[TBL] [Abstract][Full Text] [Related]
19. Streptogramins for the treatment of infections caused by Gram-positive pathogens.
Reissier S; Cattoir V
Expert Rev Anti Infect Ther; 2021 May; 19(5):587-599. PubMed ID: 33030387
[TBL] [Abstract][Full Text] [Related]
20. Novel antibacterial agents for the treatment of serious Gram-positive infections.
Abbanat D; Macielag M; Bush K
Expert Opin Investig Drugs; 2003 Mar; 12(3):379-99. PubMed ID: 12605562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
